The tools of the trade: A state of the art "How to Assess Cognition" in the patient with Parkinson's disease

Movement Disorders

Volumn 29, Issue 5, 2014, Pages 584-596

  Marras, Connie ^a   Tröster, Alexander I ^b   Kulisevsky, Jaime ^c   Stebbins, Glenn T ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Assessment; Cognition; Neuropsychology; Parkinson's disease

Indexed keywords

COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; MEDICAL SOCIETY; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; BEHAVIOR; COGNITION DISORDERS; COMPLICATION; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BEHAVIOR; COGNITION; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84898795116     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25874     Document Type: Review

References (116)

1. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA, Brayne CEG. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Pt 7):1787-1798.
2. Irwin DJ, White MT, Toledo JB, et al. Neuropathological substrates of Parkinson's disease dementia. Ann Neurol 2012;72:587-598.
3. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-307.
4. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(Pt 11):2958-2969.
5. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain 1986;109:845-883.
6. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease. Mov Disord 2011;26(S3):S48-S80.
7. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21(9):1343-1349.
8. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurology 2013;70:580-586.
9. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz 1837.
10. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
11. Shaskin D, Yarnell H, K A. Physical, psychiatric, and psychometric studies of post-encephalitic parkinsonism. J Nerv Mental Disord 1942;96:652-662.
12. Diller L, Riklan M, Cooper IS. Preoperative response to stress as a criterion of the response to neurosurgery in Parkinson's disease. J Amer Geriatr Soc 1956;4:1301-1308.
13. Stebbins GT. Neuropsychological testing. In: Goetz CG, ed. Textbook of clinical neurology, 2nd edition. Philadelphia: Elsevier Science, 2003:531-549.
14. Sweet JJ, Meyer DG, Nelson NW, PJ M. The TCN/AACN 2010 "salary survey": professional practices, beliefs, and incomes of U.S. neuropsychologists. Clin Neuropsychologist 2011;25:12-61.
15. Fields JA, Tröster AI. Neuropsychological aspects. In: Pahwa R LK, ed. Handbook of Parkinson's disease 5th ed. Boca Raton, FL: CRC Press, 2013.
16. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22(16):2314-2324.
17. Kudlicka A, Clare L, Hindle JV. Executive functions in Parkinson's disease: systematic review and meta-analysis. Mov Dis 2011;26:2305-2315.
18. Henry JD, Crawford JR. Verbal fluency deficits in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc 2004;10:608-622.
19. Siegert RJ, Weatherall M, Taylor KD, Abernethy DA. A meta-analysis of performance on simple span and more complex working memory tasks in Parkinson's disease. Neuropsychology 2008;22:450-461.
20. Whittington CJ, Podd J, Kan MM. Recognition memory impairment in Parkinson's disease: power and meta-analyses. Neuropsychology 2000;14:233-246.
21. Tröster AI, Woods SP, Morgan EE. Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices. Archives of Clinical Neuropsychology 2007;22:711-718.
22. Broeders M, Velseboer DC, de Bie R. Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study. J Int Neuropsychol Soc 2013;19:695-708.
23. Kulisevsky J, Garcia-Sanchez C, Berthier ML. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-626.
24. Weaver FM, Follett KA, Stern MB. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 2012;79:55-65.
25. Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease. Mov Disord 2013;28:1034-1049.
26. Dobkin RD, Menza M, KL B. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 2010;22:188-195.
27. Nell V. Luria in Uzbekistan: the vicissitudes of cross-cultural neuropsychology. Neuropsychol Rev 1999;9:45-52.
28. Ramlall S, Chipps J, Bhigjee AL, Pillay BJ. Screening a heterogeneous elderly South African population for cognitive impairment: the utility and performance of the Mini- Mental State Examination, Six Item Screener, Subjective Memory Rating Scale and Deterioration Cognitive Observee. Afr J Psychiatry 2013;16(6):Epub ahead of print.
29. Kaplan E. A process approach to neuropsychological assessment. In: Boll T BB, ed. Clinical neuropsychology and brain function: Research, measurement and practice. Washington, DC: American Psychological Association, 1988:127-167.
30. Woodhouse J, Heyanka DJ, Scott J, et al. Efficacy of the ANAM General Neuropsychological Screening Battery (ANAM GS) for detecting neurocognitiv e impairment in a mixed clinical sample. Clin Neuropsychol 2013;27:376-385.
31. Hanna-Pladdy B, Enslein A, Fray M, Gajewski BJ, Pahwa R, Lyons KE. Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA. In J Neurosci 2010;120:538-543.
32. Hawkins KA, Jennings D, Vincent AS, Gilliland K, West A, Marek K. Traditional neuropsychological correlates and reliability of the automated neuropsychological assessment metrics-4 battery for Parkinson's disease. Parkinsonism Relat Disord 2012;18:864-870.
33. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013. J Neurol Neurosurg Psychiatry 2013;84:1258-1264.
34. Pfeiffer HC, Lokkegaard A, Zoetmulder M, Friberg L, Werdelin L. Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurologica Scandinavica 2013:Epub ahead of print.
35. Bauer RM, Iverson GL, Cernich AN, Binder LM, Ruff RM, Naugle RI. Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology. Arch Clin Neuropsychol 2012;27:362-373.
36. Tröster AI, Browner N. Movement disorders with dementia in older adults. In: Ravdin LD, Katzen HL, eds. Handbook on the neuropsychology of aging and dementia. New York: Springer, 2013.
37. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.
38. Paolo AM, Tröster AI, Glatt SL, Hubble JP, Koller WC. Differentiation of the dementias of Alzheimer's and Parkinson's disease with the Dementia Rating Scale. J Geriatr Psychiatry Neurol 1995;8:184-188.
39. Brown RG, Lacomblez L, Landwehrmeyer BG. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133:2382-2393.
40. Pillon B, Blin J, Vidailhet M. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995;45:1477-1483.
41. Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Parkinson's disease and Alzheimer's disease 1986;36:1179-1185.
42. Robbins TW, James M, Owen AM. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57:79-88.
43. Soliveri P, Monza D, Paridi D. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000;69:313-318.
44. Lee W, Williams DR, Storey E. Cognitive testing in the diagnosis of parkinsonian disorders: a critical appraisal of the literature. Mov Disord 2012;27:1243-1254.
45. Rittman T, Ghosh BC, McColgan P, et al. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 2013;84:544-551.
46. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006;5:578-588.
47. Smeding HM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:754-760.
48. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011;82:1033-1037.
49. Olde Dubbelink KTE, Hillebrand A, Twisk JWR, et al. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology 2014;82:263-270.
50. Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010;25:1170-1176.
51. Cahn DA, Sullivan EV, Shear PK, Pfefferbaum A, Heit G, Silverberg G. Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease. Arch Clin Neuropsychol 1998;13:575-583.
52. Dymek M, Marson D, Atchison P. Executive dysfunction and capacity to consent to treatment in Parkinson's disease [Abstract]. Arch Clin Neuropsychol 1999;14:48.
53. Karlawish J, Cary M, Moelter ST. Cognitive impairment and PD patients' capacity to consent to research. Neurology 2013;81:801-807.
54. Martin RC, Triebel KL, Kennedy RE. Impaired financial abilities in Parkinson's disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord 2013;19:986-990.
55. Ranchet M, Paire-Ficout L, Uc EY, Bonnard A, Sornette D, Broussolle E. Impact of specific executive functions on driving performance in people with Parkinson's disease. Mov Disord 2013;28:1941-1948.
56. Folstein MF, Folestine SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-198.
57. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
58. Mioshi E, Dawson K, Mitchell J. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Am J Geriatr Psychiatry 2006;21:1078-1085.
59. Roth M, Huppert FA, Mounjoy CQ, Tym E. CAMDEX: the Cambridge examination for mental disorders. Cambridge: Cambridge University Press, 1988.
60. Mattis S. Dementia Rating Scale professional manual. Odessa, FL: Psychological Assessment Resources, 1988.
61. Randolph C. Repeatable battery for the assessment of neuropsychological status manual. San Antonio, TX: The Psychological Corporation, 1998.
62. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;41:1356-1364.
63. Emre M, Aarstland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New Eng J Med 2004;351:2509-2518.
64. Duff K, Patton D, Schoenberg MR. Age- and education-corrected independent normative data for the RBANS in a community dwelling elderly sample. Clin Neuropsychologist 2003;17:351-366.
65. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999;28:39-43.
66. Nazem S, Siderowf AD, Duda JE. Montreal Cognitive Assessment performance in patients with Parkinson's disease with "normal" global cognitive function according to Mini-Mental State Examination score. J Am Geriatr Soc 2009;57:304-308.
67. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2011;75:1717-1725.
68. Komadina NC, Terpening Z, Haung Y. Utility and limitations of Addenbrooke's Cogntiive Examination - Revised for detecting mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord 2011;31:349-357.
69. Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR. Predictors of cognitive outcomes in early Parkinson's disease patients: the National Institutes of Health Exploratory Trials in Parkinson's Disease (NET-PD) experience. Parkinsonism Relat Disord 2010;15:507-512.
70. Stebbins GT. Cognitive Impairment Screening Scales. In: C Sampaio CGAS, ed. Rating Scales in Parkinson's Disease Clinical Practice and Research. New York, NY: Oxford University Press, 2012:3-9.
71. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009;24:1103-1110.
72. Pagonabarraga J, Kulisevsky J, Llebaria G. PDD-Short Screen: a brief congitive test for screening dementia in Parkinson's disease. Mov Disord 2010;25:440-446.
73. Kalbe E, Calabrese P, Nils K. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008;14:92-101.
74. Mahieux F, Michelet D, Manifacier MJ. Mini-mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. Behav Neurol 1995;8:15-22.
75. Pagonabarraga J, Kulisevsky J, Llebaria G. Parkinson's Disease - Cognitive Rating Scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23:998-1005.
76. Marinus J, Visser M, Verwey NA. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-1228.
77. Albert MS, DeKosky ST, Dickson D. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 2011;7:270-279.
78. McKhann GM, Knopman DS, Chertkow H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dementia 2011;7:263-269.
79. Riedel O, Klotsche J, Spottke A. Cognitive impairment in 873 patients with idiopathic Parkinson's disease results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008;255:255-264.
80. Forjaz MJ, Frades-Payo B, Rodriquez-Blazques C, Ayala A, Martinez-Martin P. Should the SCOPA-COG be modified?: a Rasch analysis perspective. Eur J Neurol 2010;17:202-207.
81. Serrano-Duenas M, Calero B, Serrano S, Serrano M, Goronel P. Metric properties of the Mini-Mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease. Mov Disord 2010;25:2555-2563.
82. Fernández de Bobadilla R, Pagonabarraga J, Martinez-Horta S. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 2013;28:1376-1383.
83. Martinez-Martin P, Prieto-Jurczynska C, Frades-Payo B. Psychometric attributes of the Parkinson's Disease - Cognitive Rating Scale. An independent validation study. Revista de Neurologia 2009;49:393-398.
84. Santangelo G, Barone P, Abburzzese G, Ferini-Strambi L, Antonini A. Validation of the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Neurol Sci 2013;Epub ahead of print.
85. Dujardin K, Duhamel A, Delliaux M, Thomas-Anterion C, Destee A, Defebvre L. Cognitive complaints in Parkinson's disease: its relationship with objective cognitive decline. J Neurol 2010;257:79-84.
86. Kalbe E, Salmon E, Perani D, et al. Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. Dement Geriatr Cogn Disord 2005;19(5-6):349-356.
87. Holdnack HA. Wechsler Test of Adult Reading: WTAR. San Antonio: The Psychological Corporation, 2001.
88. Nelson HE. National Adult Reading Test. Windsor, UK: NFER-Nelson, 1982.
89. Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013;28:626-633.
90. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-1455.
91. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
92. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-2186.
93. Troster AI. A Precis of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson's Disease and a Proposal of Preliminary Research Criteria. J Int Neuropsychol Soc 2011:1-14.
94. Gallagher DA, Goetz CG, Stebbins G, Lees AJ, Schrag A. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord 2012;27:79-83.
95. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
96. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19:448-450.
97. Feldman H, Sauter A, Donald A, et al. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:89-95.
98. Godefroy O, Azouvi P, Robert P, Roussel M, LeGall D, Meulemans T. Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol 2010;68:855-864.
99. Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 2004;42:1212-1222.
100. Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003;9:17-24.
101. Aretouli E, Brandt J. Everyday functioning in mild cognitive impairment and its relationship with executive cognition. Int J Geriatr Psychiatry 2010;25:224-233.
102. Sabbagh MN, Lahti T, Connor DJ, et al. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:327-334.
103. Sabbagh MN, Silverberg N, Bircea S, et al. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord 2005;11:311-315.
104. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008;23:790-796.
105. Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, et al. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. Parkinsonism Relat Disord 2013;19:812-817.
106. Martinez-Martin P. Dementia in Parkinson's disease: Usefulness of the pill questionnaire. Mov Disord 2013;28:1832-1837.
107. Reginold W, Armstrong MJ, Duff-Canning S, et al. The pill questionnaire in a nondemented Parkinson's disease population. Mov Disord 2012;27:1308-1311.
108. Weintraub D, Rubright JD, Karlawish J, Rick J, Goldmann R. Psychometric properties of the Brief Penn Daily Activities Questionnaire (PDAQ) for Parkinson's disease [Abstract]. Mov Disord 2013;28(Suppl 1):308.
109. Tarbuck AF, Paykel ES. Effects of major depression on the cognitive function of younger and older subjects. Psychological Med 1995;25:285-295.
110. Tröster AI, Stalp LD, Paolo AM, Fields JA, Koller WC. Neuropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995;52:1164-1169.
111. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
112. Foster PS, Drago V, Yung RC, Skidmore FM, Skoblar B, Shenal BV. Anxiety affects working memory only in left hemibody onset Parkinson disease patients. Cogn Behav Neurol 2010;23:14-18.
113. Robinson OJ VK, Cornwell BR, Grillon C. The impact of anxiety upon cognition: perspectives from human threat of shock studies. Frontiers Hum Neurosci 2013;In Press.
114. Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R, Ferrarese C. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002;17:366-371.
115. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1992;55:377-382.
116. Kulisevsky J, Asuncion A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132.